Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma
Metrics: PDF 404 views | Full Text 744 views | ?
Arvin Medhat1, Alla Arzumanyan2 and Mark A. Feitelson2
1 Department of Molecular Cell Biology, Azad University, North Unit, Tehran, Iran
2 Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA, USA
|Mark A. Feitelson,||email:||firstname.lastname@example.org|
Keywords: chronic liver disease; hepatocellular carcinoma; HBx; functional cure; epigenetic
Received: May 31, 2021 Accepted: September 04, 2021 Published: November 23, 2021
Hepatitis B virus (HBV) is a human pathogen that has infected an estimated two billion people worldwide. Despite the availability of highly efficacious vaccines, universal screening of the blood supply for virus, and potent direct acting anti-viral drugs, there are more than 250 million carriers of HBV who are at risk for the sequential development of hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). More than 800,000 deaths per year are attributed to chronic hepatitis B. Many different therapeutic approaches have been developed to block virus replication, and although effective, none are curative. These treatments have little or no impact upon the portions of integrated HBV DNA, which often encode the virus regulatory protein, HBx. Although given little attention, HBx is an important therapeutic target because it contributes importantly to (a) HBV replication, (b) in protecting infected cells from immune mediated destruction during chronic infection, and (c) in the development of HCC. Thus, the development of therapies targeting HBx, combined with other established therapies, will provide a functional cure that will target virus replication and further reduce or eliminate both the morbidity and mortality associated with chronic liver disease and HCC. Simultaneous targeting of all these characteristics underscores the importance of developing therapies against HBx.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.